Arrayit Corporation Logo

Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.  - Powerful Science for Life™

Corporate - Media & Press - Press Release

Arrayit Corporation Showcases Advanced Robotic Microarray Technology at Laboratory Automation Conference.

Arrayit Corporation, January 21, 2014 9:00 AM, EST

SUNNYVALE, Calif.--(BUSINESS WIRE)--Arrayit Corporation (OTCBB: ARYC), a life sciences and molecular diagnostics leader, is currently showcasing the company's advanced robotic systems for microarray printing and scanning at the Society for Laboratory Automation and Screening Conference in San Diego, California, USA from January 18-22, 2014. Sponsored by Agilent Technologies, Molecular Devices, Thermo Scientific, and other automation leaders, the conference tagline "An exceptional array of answers" highlights the central role of microarray technology in drug discovery and screening, biomarker identification, nanotechnology, bioinformatics and other conference focus areas.

Arrayit's patented and proprietary robotic systems utilize micro-robotics, linear drive technology, nanoliter and picoliter contact dispensing, real-time auto-focusing and other advanced approaches to empower the full spectrum of microarray applications required to explore the human genome and proteome, decipher human illnesses, diagnose diseases pre-symptomatically and identify safer and more efficacious medicines. Arrayit offers its 4,000 worldwide technology installations the advantages of flexibility, affordability and high performance in personal and industrial scale product offerings that are intuitive and readily deployed.

Arrayit completed its most successful year as a public company in 2013 by raising more than $2.2m in equity capital, securing financial advice from small cap expert Irwin Zalcberg, adding biotech expert Sid Taubenfeld to the Board, retaining Phil Ruben as General Counsel, leveraging the investor relations expertise of IMS, moving into a new company headquarters, hiring DOCRO, beginning CLIA and ISO laboratory certification and preparing for OvaDx® FDA submission. The company carries significant momentum into the new fiscal year after recording a company-best 150 qualified sales leads at last week's Plant and Animal Genome Conference.

About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
- Powerful Science for Life
Visit http://arrayit.com/ for more information.

Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and in Form 10-Q for the quarterly period ended September 30, 2013.

Investor Relations
Institutional Marketing Services (IMS)
John Nesbett, 203-972-9200
jnesbett@institutionalms.com
Jennifer Belodeau, 203-972-9200
jbelodeau@institutionalms.com
 

 

Copyright 1993-2017 Arrayit Corporation. All rights reserved.